INTRODUCTION {#S1}
============

Guillain-Barré syndrome (GBS) consists of an acute demyelinating neuropathy involving the peripheral nervous system. It causes weakness, paralysis, and, in some cases, leads to death \[[@ref1]-[@ref3]\]. GBS is regarded to be a rare autoimmune disease, in which the body is attacked by its own immune system \[[@ref3]-[@ref5]\].

GBS incidence ranges from 0.8 to 1.9 per 100,000 persons/ year, being more frequent among males, and the incidence increase with age \[[@ref1], [@ref2], [@ref6], [@ref7]\]. So far, the precise causes that trigger the disease are not well known. It has been reported that GBS is preceded by an infection of the gastrointestinal or respiratory tract in 2/3 of cases. It has been also linked to some viral infections, and even to influenza vaccination \[[@ref5], [@ref8]-[@ref11]\].

The association of GBS with influenza vaccination was first reported in 1976, when the seasonal vaccination campaign was stopped in the United States due to an excess of GBS cases (relative risk \[RR\]: 7-8) \[[@ref12]\]. However, few studies addressing the potential relationship of GBS to influenza vaccination were published between 1976 and 2009. Since the pandemic outbreak of influenza A in 2009, the vaccine A/ H1N1/2009 were rapidly developed, manufactured and commercialised, and surveillance systems were reinforced, adapted or set up with the aim of identifying as early as possible any incidence excess of GBS, notably in the United States, wherein an increased risk of GBS associated to influenza vaccine was found \[[@ref13], [@ref14]\].

While isolated studies on vaccination campaigns and active and passive notification of GBS cases by surveillance systems have been conducted; so far, little research has been devoted to synthesising the results from epidemiological studies \[[@ref14], [@ref15]\]. In 2015, we carried out a meta-analysis with the aim of studying the possible relationship between GBS and influenza vaccination. Now, in this article, we present the results of a systematic review of the literature, whose objective was to analyze the new data that has been appearing since the publication of our meta-analysis \[[@ref16]\].

METHODS {#S2}
=======

We reviewed the databases PubMed, EMBASE, and Web of Knowledge (WoS) covering the period 1-May-2014 / 20-July-2017. We used the same search terms and study selection criteria as in our prior meta-analysis \[[@ref16]\]. The search was conducted by combining the terms *Influenza vaccine\* AND Guillain-Barré syndrome*, with no restrictions. Criteria for the inclusion of studies were the following: (a) observational studies evaluating the risk of GBS associated with any of the influenza vaccines, and (b) studies reporting risk measures expressed as relative risk (RR), odds ratio (OR), relative incidence (RI), or incidence rate ratio (IRR); though, in the present review, we included a new risk measure as well, namely the hazard ratio (HR). In all cases, we considered the respective 95% confidence intervals (95% CI).

RESULTS {#S3}
=======

The bibliographic review enabled us to identify 107 studies ([figure 1](#F1){ref-type="fig"}): PubMed (n=39), EMBASE (n=44), and WoS (n=24). First, we eliminated the articles lacking an abstract (n=15), those containing lectures and oral comments (n=7), those notifying isolated cases (n=3), duplicated articles (n=30), and articles previously reviewed or included in our earlier meta-analysis (n=10) \[[@ref16]\]. Then, we read the article abstracts and/or the whole texts of the potentially eligible studies. Some of the exclusion criteria were the following: a) studies based on the results from surveillance system notifications of serious and non-serious adverse effects supposedly related to any of the influenza vaccines that did not report any estimates of GBS risk following influenza vaccination \[[@ref17]-[@ref22]\], b) pharmacovigilance studies on GBS that included any types of paediatric immunisation \[[@ref23]\], c) studies addressing the potential triggering agents for GBS \[[@ref24]\], c) studies based on risk simulation of GBS and other autoimmune diseases associated with either infections or influenza vaccination \[[@ref25], [@ref26]\], d) studies whose design or analysis of data on vaccine safety was considered not to be suitable \[[@ref27], [@ref28], [@ref29]\], and e) studies focusing on other influenza vaccination adverse effects, such as polyneuropathies, neurological events, Zika virus or surgery

![Flow diagram showing identification of studies meeting inclusion criteria.](revespquimioter-32-288-g001){#F1}

Only 3 studies met all the eligibility criteria ([table 1](#T1){ref-type="table"}), as follows: Kim et al.; 2015 \[[@ref30]\], in which an increased risk of GBS was observed in South Korea following the administration of the adjuvanted and non-adjuvanted pandemic vaccine A/ H1N1, with the risk expressed as a rate ratio (RR=1.46, 95% CI: 1.26-1.68); Ghaderi et al.; 2015 \[[@ref31]\], in which the authors found an increased risk of GBS in Norway within 42 days after the administration of the pandemic vaccine A/H1N1 (Pandemrix®), with the risk expressed as a hazard ratio (HR= 1.1, 95% CI: 0.51-2.43); and Sandhu et al.; 2017 \[[@ref7]\], which focused on the outcomes for four influenza vaccination campaigns (from 2010/11 to 2013/14). In this latter study, the authors reported a statistically non-significant increased risk of GBS (RR=1.25, 95% CI: 0.96-1.63) for the season 2010/1011 among a Medicare population (USA); with the risk being much lower than that observed in the season 2009/10 (RR=1,98, 95% CI: 1.42- 2.76), while an increased risk was not found in the remaining three vaccination campaigns (i. e. from 2011/12 to 2013/14).

###### 

Characteristics of selected observational studies.

  Authors/Year          Study location   GBS cases   Design   Influenza vaccine   Risk
  --------------------- ---------------- ----------- -------- ------------------- -----------------------------
  Ghaderi et al. 2016   Norwey           410         Cohort   A(H1N1) 2009        HR=1.11 (95% CI 0.51-2.43)
  Kim et al. 2016       Korea            245         Cohort   A(H1N1) 2009        RR=1.46 (95% CI: 1.26-1.68)
  Sandhu et al. 2017    USA                          SCRI     2010/11 seasonal    RR=1.25 (95% CI: 0.96-1.63)

SCRI: Self-controlled risk interval (SCRI) design; HR: Hazard ratio; RR=risk relative.

DISCUSSION {#S4}
==========

Our systematic review focused on the new data about influenza vaccination and its potential association with GBS published after the publication of our prior meta-analysis \[[@ref16]\]. The review of the published articles enabled us to identify only three epidemiological studies that fulfilled the eligibility criteria \[[@ref7], [@ref30], [@ref31]\]. It is striking the shortage of published studies estimating the magnitude of the GBS risk linked to or following the administration of the influenza vaccines when taking into account that the relevant health authorities have been emphasizing the necessity for continuously monitoring the potential adverse effects of influenza vaccination \[[@ref21], [@ref28], [@ref29], [@ref32]\] .Furthermore, it is well known the importance of having post-commercialisation studies on the influenza vaccines \[[@ref17]-[@ref20], [@ref22], [@ref33]\], as well as near real-time pharmacovigilance studies aimed at rapidly identifying any risk excess of GBS following influenza vaccination \[[@ref7], [@ref13]\]. Despite these studies have the disadvantage that it is difficult to quantify any causal associations; they present the advantage of enabling us to rapidly detect the signals for potential adverse events following immunization (AEFI). In addition, such studies may constitute the starting basis for further investigation on potential causal associations. Therefore, it should be emphasised the importance of conducting and reporting multicentre, collaborative, epidemiological studies with prolonged follow-up periods aimed to identifying and quantifying potential unexpected or rare adverse effects (e. g. GBS) following influenza vaccination \[[@ref7], [@ref15], [@ref34], [@ref35]\].

Concerning the risk reported in the observational studies selected for our systematic review ([table 1](#T1){ref-type="table"}) and our previously published meta-analysis ([table 2](#T2){ref-type="table"}), it should be pointed out that, in one of the studies selected for our review, Kim *et al*. \[[@ref30]\] concluded that the pandemic vaccine (pH1N1) was associated with an increased risk of GBS expressed as a relative risk of 1.46; (95% CI, 1.26-1.68). This finding is in keeping with the results from two meta-analyses \[[@ref15], [@ref16]\], which reported a GBS risk estimate expressed as a relative incidence of 2.09 (95% CI: 1.28-3.42) and a relative risk of 1.84 (95% CI: 1.36- 2.50), respectively. The finding by *Kim* et al. is also in line with the results from other individual studies \[[@ref36]-[@ref40]\]. Another meta-analysis \[[@ref14]\] reported a statistically non-significant increased risk of GBS for the vaccine H1N1 2009 expressed as an incidence rate ratio of 2.35 (95% CI: 1.42-4.01), which concurs with the results from several other individual studies \[[@ref33], [@ref41]\]. The second study identified by our systematic review was that by Ghaderi et al. \[[@ref31]\], who reported that the pandemic vaccine (pH1N1) was not associated with an increased risk of GBS. This finding is in keeping with the results from some previous studies \[[@ref34], [@ref42]\]. Finally, the third study we selected, that is, that by *Sandhu* et al. \[[@ref7]\] , focused on the outcomes of four influenza vaccination campaigns. The authors reported a statistically non-significant increased risk expressed as a relative risk (RR=1.25, 95% CI: 0.96-1.63) in the season 2010/11. However, they failed to observe any risk excess in the remaining three seasons. In this latter study, the authors found an increased risk of GBS (RR=1.98 95% CI: 1.42-2.76) for the season 2009/10. In contrast, an investigation based on both simulation models and previously published risk estimates \[[@ref26]\] supported the hypothesis posed in an earlier study that influenza immunisation was protective against GBS, and, therefore, resulted in a decreased risk \[[@ref43]\] . At any rate, it should be borne in mind that the differences in the risk magnitudes reported in each study are small and they only approximated to the value with statistical significance by either excess or defect. On the other hand, the coverage of influenza vaccination programmes is broader every year, and this is not positively correlated with the number of hospitalisations for GBS \[[@ref44]\]. In addition, it is worth reminding that the financial burden associated with the complications derived from the infections caused by the influenza virus largely exceeds the financial costs of influenza vaccination \[[@ref45]\].

###### 

Characteristics of previous published meta-analysis.

  ----------------------------------------------------------------------------------------------------------------------------------------------
  Authors/Year               Study location                                    Design          Influenza vaccine   Risk
  -------------------------- ------------------------------------------------- --------------- ------------------- -----------------------------
  Salmon et al. 2013         USA                                               Meta-analysis   A (H1N1) 2009       IRR=2.35 (95% CI 1.2-4.01)

  Dodd et al. 2013           International [\*](#TF2-1){ref-type="table-fn"}   Meta-analysis   A (H1N1) 2009       RI= 2.09 (95%CI 1.28-3.42)

  Martín Arias et al. 2015   International                                     Meta-analysis   A(H1N1) 2009\       RR= 1.84 (95%CI 1.36-2.50)\
                                                                                               Seasonal            RR= 1.22 (95%CI 1.01-1.48)
  ----------------------------------------------------------------------------------------------------------------------------------------------

Australia, Canada, China, Denmark, Finland, The Netherlands, Singapore, Spain, The United Kingdom and The United States Databases.

IRR: Incidence rate ratio. RI: relative incidence. RR: relative risk.

Likewise, other suspected triggering agents of GBS, apart from influenza vaccination, should be taken into consideration. The current evidence indicates that previous infections are likely to play an important role in the development of GBS, notably the infections involving the upper respiratory tract or the gastrointestinal tract, those caused by the influenza virus and the so-called influenza-like infections (ILI) \[[@ref5], [@ref8]-[@ref11], [@ref46]-[@ref47]\]. One of the studies selected for our systematic review supported the hypothesis that the influenza infection is a potential triggering agent among the Norwegian population. These authors found a post-influenza infection risk expressed as a hazard ratio (HR) of 4.89 (95% CI: 1.17-20.36), this risk magnitude being much higher than that observed after influenza vaccination (HR=1.11 95%CI: 0.51-2.43) \[[@ref31]\]. Another study we selected for our review reported that in 82.5% of GBS cases there had been a previous respiratory or gastrointestinal infection \[[@ref30]\]. This finding is in agreement with the results from a study reporting a strong association of GBS with either previous respiratory or gastrointestinal infections or previous unspecific viral infections (odds ratio=7.73, 95% CI: 3.60-16.61) \[[@ref46]\]. The results from other studies also support the aforementioned hypothesis, since the authors noted an important increment in the risk of GBS following a previous infection. Thus, Tam et al. reported an odds ratio (OR) of 18.6, (95% CI: 7.5-46.4), whilst Stowe *et al*. spoke of a relative risk (RR) of 7.35, (95% CI: 4.36-12.38) within the first 60 and 90 days of an influenza-like illness (ILI), respectively \[[@ref8], [@ref10]\].

Another potential triggering factor for GBS reported in the studies we have reviewed is surgery. According to the results of a study conducted in Finland, the relative risk of developing GBS within the first 6 weeks after surgery is 13.1-fold higher (95% CI: 5.68-30.3, P ≤ 0.0001) \[[@ref24]\]. This finding concurs with the results of other studies \[[@ref48], [@ref49]\]. Also, it has been reported an increase in the notified GBS cases related to the ZiKa virus infection \[[@ref50]\].

With regard to the type of study, in our systematic review we found that some of the published studies were based on the notifications of supposed adverse reactions related to the different influenza vaccines, such as the notifications by the Vaccine Adverse Reporting System (VAERS). However, it should be kept in mind that, while these notifications are very useful for the quick detection of safety concerns, they are not of value for establishing potential cause-effect relationships.

Epidemiological studies with self-controlled design, like self-controlled case series, self-controlled risk-interval, case-centred and case-population studies, represent the most suitable approach in the field of observational studies, since, in this type of investigation, each case acts as its own control. In addition, these studies are adjusted for all confounding factors that may vary with time. In our earlier meta-analysis, 24 of the 39 weighted studies used the self-controlled design \[[@ref16]\]. Nevertheless, few studies have reported the risk estimates adjusted for either seasonality or subjects' previous infections \[[@ref15], [@ref34]\]. In the three studies selected for the present systematic review, the authors referred to seasonality as an important factor. In one of these studies, a larger number of cases was found in November, January and February \[[@ref30]\], whereas another study showed a significant increased risk of GBS during the pandemic period compared to other time intervals \[[@ref31]\].

The studies selected for our systematic review (i.e. 3/107) estimated the risk of GBS following influenza vaccination, showing a very small risk excess magnitude when taking into account the financial and health benefits obtained from immunisation. Indeed, the risk excess is very small; however, other potential explanatory factors should be considered, such as the low incidence rate of GBS, the temporal coincidence with the periods with the largest circulation of the influenza virus, the occurrence of respiratory and gastrointestinal infections, or the administration of the vaccine for either seasonal (October-November) or pandemic influenza. All the above factors may make it difficult to interpret the results from the epidemiological studies on the potential relationship between influenza vaccination and GBS.

In relation to the differences in the estimates of the risk as reported in the different studies, they can be combined or reconciled, because post-vaccination GBS is a rare condition \[[@ref16]\]. According to two studies, the risk estimates obtained with the case-population approach (CPA) are consistent with the odds ratios in the case-control studies, and discrepancies were observed only with the vaccine A (H1N1) in Sweden and UK \[[@ref27], [@ref28]\]. In a review of the statistical methods used in vaccine surveillance studies, the authors indicated that up to 37 different methods can be used depending on the kind of analysis \[[@ref29]\].

The studies selected for our systematic review reported that GBS was more prevalent among males and elderly people, which is in agreement with the results from earlier investigation \[[@ref1]-[@ref2], [@ref14]\]. Thus, in 1983 a study was published, whose authors stated that GBS was more frequent in males, the incidence increased with age, and incidence rates were more heightened among white race individuals \[[@ref51]\].

Another issue of concern for particularly sensitive populations is influenza vaccine safety for pregnant women and children. Further investigation is needed to provide information regarding influenza vaccination during pregnancy. This issue was addressed by only three of the studies we found in our initial search \[[@ref22], [@ref52], [@ref53]\]. Thus, in a large cohort of pregnant women to whom the vaccine A/H1N1 was given, the authors did not find any cases of GBS within the first 42 days after vaccination \[[@ref52]\]. Nevertheless, it was notified a case of GBS that occurred 24 days after the administration of a trivalent influenza vaccine (TIV) to a pregnant woman during the 2013/14 campaign \[[@ref53]\]. The pharmacovigilance system deployed in Latin America and the Caribbean to monitor the potential adverse effects of the vaccine A/H1N1 reported increased adverse effect rates among pregnant women as compared to those among healthcare personnel and patients with chronic diseases \[[@ref22]\], which might be explained by differences in the influenza virus strains that circulate in both hemispheres.

Few studies initially screened for our systematic review addressed the potential relationship between influenza vaccination and GBS in paediatric populations \[[@ref47], [@ref54]-[@ref56]\]. A prospective epidemiological study conducted in the UK based on the UK pharmacovigilance system (British Paediatric Surveillance Unit System) \[[@ref47]\] showed that GBS and "Miller Fisher syndrome" associated with the pandemic influenza vaccine were more prevalent among boys compared to girls. In addition, this study revealed that most of the affected children had suffered a previous infection, and that the cases associated with the pandemic vaccine were more frequent than those associated with the seasonal vaccine, though this difference did not reach statistical significance. This finding is in keeping with the results of another study \[[@ref7]\], and coincides with those of our previous meta-analysis \[[@ref16]\]. In a safety study in children aged 6-12 months conducted in Taiwan, the authors failed to find serious adverse events within the first 7 days after the administration of a killed TIV during the 2010/11 campaign \[[@ref54]\]. In a USA pharmacovigilance study with the live quadrivalent influenza vaccine (LAIV4), it was found that the most frequently notified non-fatal serious adverse reactions were those involving the nervous and respiratory systems. Neurological adverse reactions were more frequent in children than among adults, and GBS was the second most frequently notified neurological event \[[@ref56]\]. This children's susceptibility may be related either to genetic heredity or to the type of vaccine, since live vaccines have not been sufficiently investigated in children aged under 2 years, and the established safety of a given influenza vaccine cannot be extrapolated to the remainder of vaccines \[[@ref55]\].

The advent of inmunogenomics, proteomics, genetic engineering, biostatistics, and computational studies may help to find biomarkers that allow us to identify the differences in both individual and group pathophysiologic mechanisms. In turn, these differences might explain why certain individual or groups present a greater susceptibility to autoimmune diseases following vaccination. Some genetic polymorphisms (e. g. HLA-DQB1\*) are known to render carriers more susceptible to develop GBS \[[@ref57], [@ref58]\], while computational simulation studies (*in silico*) have identified some genes involved in 4 types of autoimmune diseases, including GBS, a disease in which as many as 73 genes may be implicated \[[@ref25]\]. Nonetheless, a meta-analysis based on Asian and Caucasian populations did not find any relationships between alleles and risk of GBS \[[@ref59]\].

The present systematic review we conducted after the publication of our previous meta-analysis seems to confirm the results of such a meta-analysis. Therefore, GBS should be considered an infrequent adverse effect of influenza vaccination, which should not negatively influence the vaccination acceptance. However, unfortunately, very few of the studies meeting inclusion criteria that we found in our systematic review presented sufficient quality. This fact sharply contrasts with the current consensus as to the need of continuously monitoring the safety of influenza vaccines. Therefore, one would expect to find a larger number of competent studies that allow us to detect near real-time signals. However, today it is not easy to find such studies in the medical literature.
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